Belgium - angol - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

intervet international b.v. - bovine rotavirus (inactivated) ; escherichia coli f5 fimbrial adhesin ; bovine coronavirus (attenuated) - emulsion for injection - bovine coronavirus; escherichia coli antigen; bovine rotavirus - bovine rotavirus + bovine coronavirus + escherichia - cattle

Belgium - angol - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bioveta a.s. - bovine herpes virus 1 (live), ge negative - lyophilisate and solvent for suspension for injection - bovine herpes virus type 1 (bhv1), live, attenuated - bovine rhinotracheitis virus (ibr) - cattle

Belgium - angol - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

zoetis belgium sa-nv - bovine rotavirus ; bovine coronavirus ; escherichia coli (inactivated) - suspension for injection - bovine rotavirus; bovine coronavirus; escherichia coli, inactivated - bovine rotavirus + bovine coronavirus + escherichia - cattle

Új-Zéland - angol - Ministry for Primary Industries

hipra new zealand limited - bovine viral diarrhoea virus (inactivated); parainfluenza-3 virus (inactivated); infectious bovine rhinotrocheitis virus (inactivated) - bovine viral diarrhoea virus (inactivated) 0 vaccine; parainfluenza-3 virus (inactivated) 0 vaccine; infectious bovine rhinotrocheitis virus (inactivated) 0 vaccine - vaccine

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - live attenuated human rotavirus 1e+006 ccid50 ((rix 4414 strain)) - oral suspension - 1e+006 ccid50 - active: live attenuated human rotavirus 1e+006 ccid50 ((rix 4414 strain)) excipient: di-sodium adipate dulbecco's modified eagle medium sucrose water for injection - rotarix is indicated for the prevention of rotavirus gastroenteritis

Ausztrália - angol - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - bordetella bronchiseptica; canine parainfluenza virus; aluminium hydroxide - misc. vaccines or anti sera - bordetella bronchiseptica vaccine-microbial active 0.05 ug/ml; canine parainfluenza virus vaccine-viral active 1000000.0 tci50/ml; aluminium hydroxide mineral-aluminium-base other 3.0 mg/ml - immunotherapy - dog - with exclusions see label - bordetella spp. | canine parainfluenza | bordetella bronchiseptica

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - polio virus type 1 29 dagu (mahoney by parallel line method (equiv to 40 dagu by sigmoid method)); polio virus type 2 7 dagu (mef1 by parallel line method (equiv to 8 dagu by sigmoid method)); polio virus type 3 26 dagu (saukett by parallel line method (equiv to 32 dagu by sigmoid method)) - suspension for injection - active: polio virus type 1 29 dagu (mahoney by parallel line method (equiv to 40 dagu by sigmoid method)) polio virus type 2 7 dagu (mef1 by parallel line method (equiv to 8 dagu by sigmoid method)) polio virus type 3 26 dagu (saukett by parallel line method (equiv to 32 dagu by sigmoid method)) excipient: formaldehyde phenoxyethanol polysorbate 80 water for injection - ipol is indicated for active immunisation of infants, children and adults for the prevention of poliomyelitis. recommendations for the use of live and inactivated poliovirus vaccines are described in the national immunisation guidelines. 1. general recommendations. it is recommended that all infants, unimmunised children and adolescents not previously immunised be vaccinated routinely against paralytic poliomyelitis. ipol should be offered to patients who have refused opv, or in whom opv is contraindicated. 2. ipol is also indicated for: · the primary vaccination of immunocompromised individuals of all ages (see precautions), and household contacts of such individuals (when vaccination is indicated) · unvaccinated or inadequately vaccinated (*) adults, particularly if at increased risk of exposure to live poliovirus, including: · travellers to areas or countries where poliomyelitis is epidemic or endemic; · laboratory workers handling specimens which may contain polioviruses; · health care workers in close contact with patients who may be excreting polioviruses. (*) such as those who had not completed a primary series of vaccination or not received a booster dose since infancy.

Izrael - angol - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - hepatitis a virus antigen, inactivated - suspension for injection - hepatitis a virus antigen, inactivated 25 units / 0.5 ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in children and adolescents 12 months of age and older .

Izrael - angol - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - hepatitis a virus antigen, inactivated - suspension for injection - hepatitis a virus antigen, inactivated 50 u/ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 2 years of age and older.

Izrael - angol - Ministry of Health

medici medical ltd, israel - diphtheria toxoid; filamentous haemagglutinin (fha); fimbrae tupes 2 + 3 (fim); pertactin (prn); pertussis toxoid vaccine; poliovirus type 1; poliovirus type 2; poliovirus type 3; prp of haemophilus infl. type b; tetanus toxoid - suspension for injection - pertactin (prn) 3 mcg ml; diphtheria toxoid 15 lf ml; tetanus toxoid 5 lf ml; pertussis toxoid vaccine 20 mcg ml; filamentous haemagglutinin (fha) 20 mcg ml; fimbrae tupes 2 + 3 (fim) 5 mcg ml; poliovirus type 1 40 du ml; poliovirus type 2 8 du ml; poliovirus type 3 32 du ml; prp of haemophilus infl. type b 10 mcg ml - bacterial and viral vaccines, combined - pediacel is indicated for immunization of children at or above the age of 2 months and as a booster in children up to their 7th birthday against diphtheria, tetanus, whooping cough, poliomyelitis and invasive haemophilus influenzae type b disease. in infants, three infectons are to be given intramuscularly at 2, 4 and 6 months of age followed by a booster at 18 months of age. children who have had pertusis, tetanus, diphtheria or haemophilus influenzae type b invasive disease should still be immunized since these clinical infections do not always confer immunity. children who have had natural pertussis can continue to receive pertussis - containing vaccines. human immunodeficiency virus (hiv) infected persons hiv- infected individuals, both asymptomatic and symptomatic, should be immunized with pediacel vaccine according to standard schedules.